View Future GrowthBioSmartLtd 過去の業績過去 基準チェック /56BioSmartLtdは、平均年間48.3%の収益成長を遂げていますが、 Tech業界の収益は、年間 成長しています。収益は、平均年間30.1% 20.7%収益成長率で 成長しています。 BioSmartLtdの自己資本利益率は4.8%であり、純利益率は1.9%です。主要情報48.26%収益成長率46.88%EPS成長率Tech 業界の成長-2.85%収益成長率20.71%株主資本利益率4.79%ネット・マージン1.87%前回の決算情報31 Dec 2025最近の業績更新Reported Earnings • Mar 22Full year 2024 earnings released: EPS: ₩6.00 (vs ₩915 in FY 2023)Full year 2024 results: EPS: ₩6.00 (down from ₩915 in FY 2023). Revenue: ₩484.3b (up 6.2% from FY 2023). Net income: ₩127.2m (down 99% from FY 2023). Profit margin: 0% (down from 3.9% in FY 2023). Over the last 3 years on average, earnings per share has increased by 49% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings.分析記事 • Mar 26Shareholders In BioSmartLtd (KOSDAQ:038460) Should Look Beyond Earnings For The Full StoryWe didn't see BioSmart Co.,Ltd.'s ( KOSDAQ:038460 ) stock surge when it reported robust earnings recently. We looked...Reported Earnings • Mar 23Full year 2023 earnings released: EPS: ₩915 (vs ₩38.00 in FY 2022)Full year 2023 results: EPS: ₩915 (up from ₩38.00 in FY 2022). Revenue: ₩456.2b (up 16% from FY 2022). Net income: ₩17.9b (up ₩17.2b from FY 2022). Profit margin: 3.9% (up from 0.2% in FY 2022). Over the last 3 years on average, earnings per share has increased by 124% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.すべての更新を表示Recent updatesお知らせ • Mar 13BioSmart Co.,Ltd., Annual General Meeting, Mar 27, 2026BioSmart Co.,Ltd., Annual General Meeting, Mar 27, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 36-16, oncheon-daero 1122beon-gil, chungcheongnam-do, asan South KoreaValuation Update With 7 Day Price Move • Mar 04Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₩4,360, the stock trades at a trailing P/E ratio of 15.3x. Average trailing P/E is 12x in the Tech industry in South Korea. Total returns to shareholders of 20% over the past three years.分析記事 • Feb 02What BioSmart Co.,Ltd.'s (KOSDAQ:038460) 44% Share Price Gain Is Not Telling YouBioSmart Co.,Ltd. ( KOSDAQ:038460 ) shares have continued their recent momentum with a 44% gain in the last month...New Risk • Feb 02New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 14% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (14% average weekly change). Minor Risk Market cap is less than US$100m (₩143.6b market cap, or US$99.1m).Valuation Update With 7 Day Price Move • Feb 02Investor sentiment improves as stock rises 42%After last week's 42% share price gain to ₩5,680, the stock trades at a trailing P/E ratio of 19.9x. Average trailing P/E is 10x in the Tech industry in South Korea. Total returns to shareholders of 50% over the past three years.分析記事 • Dec 15BioSmart Co.,Ltd.'s (KOSDAQ:038460) Shares Climb 44% But Its Business Is Yet to Catch UpBioSmart Co.,Ltd. ( KOSDAQ:038460 ) shares have had a really impressive month, gaining 44% after a shaky period...New Risk • Dec 15New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (9.3% average weekly change). Market cap is less than US$100m (₩100.3b market cap, or US$68.5m).Valuation Update With 7 Day Price Move • Dec 15Investor sentiment improves as stock rises 42%After last week's 42% share price gain to ₩3,970, the stock trades at a trailing P/E ratio of 13.9x. Average trailing P/E is 11x in the Tech industry in South Korea. Total returns to shareholders of 8.2% over the past three years.New Risk • Aug 30New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended September 2013. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported September 2013 fiscal period end). Minor Risk Market cap is less than US$100m (₩74.9b market cap, or US$54.0m).分析記事 • Apr 23The Market Lifts BioSmart Co.,Ltd. (KOSDAQ:038460) Shares 33% But It Can Do MoreBioSmart Co.,Ltd. ( KOSDAQ:038460 ) shareholders have had their patience rewarded with a 33% share price jump in the...New Risk • Apr 23New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 0.8% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (10% average weekly change). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (0.03% net profit margin). Shareholders have been diluted in the past year (23% increase in shares outstanding). Market cap is less than US$100m (₩102.7b market cap, or US$72.2m).分析記事 • Apr 09Is BioSmartLtd (KOSDAQ:038460) Using Too Much Debt?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Reported Earnings • Mar 22Full year 2024 earnings released: EPS: ₩6.00 (vs ₩915 in FY 2023)Full year 2024 results: EPS: ₩6.00 (down from ₩915 in FY 2023). Revenue: ₩484.3b (up 6.2% from FY 2023). Net income: ₩127.2m (down 99% from FY 2023). Profit margin: 0% (down from 3.9% in FY 2023). Over the last 3 years on average, earnings per share has increased by 49% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings.お知らせ • Mar 12BioSmart Co.,Ltd., Annual General Meeting, Mar 26, 2025BioSmart Co.,Ltd., Annual General Meeting, Mar 26, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 36-16, oncheon-daero 1122beon-gil, chungcheongnam-do, asan South KoreaNew Risk • Dec 08New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended September 2013. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported September 2013 fiscal period end). Minor Risks Shareholders have been diluted in the past year (25% increase in shares outstanding). Market cap is less than US$100m (₩74.2b market cap, or US$52.1m).分析記事 • Nov 13BioSmart Co.,Ltd. (KOSDAQ:038460) May Have Run Too Fast Too Soon With Recent 25% Price PlummetThe BioSmart Co.,Ltd. ( KOSDAQ:038460 ) share price has fared very poorly over the last month, falling by a substantial...分析記事 • Oct 14Here's Why We Think BioSmartLtd (KOSDAQ:038460) Is Well Worth WatchingFor beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Valuation Update With 7 Day Price Move • Oct 14Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₩4,205, the stock trades at a trailing P/E ratio of 10.8x. Average trailing P/E is 9x in the Tech industry in South Korea. Total loss to shareholders of 21% over the past three years.Valuation Update With 7 Day Price Move • Aug 26Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to ₩3,810, the stock trades at a trailing P/E ratio of 4.5x. Average trailing P/E is 9x in the Tech industry in South Korea. Total loss to shareholders of 42% over the past three years.分析記事 • Aug 01BioSmartLtd (KOSDAQ:038460) Seems To Be Using A Lot Of DebtSome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...分析記事 • Jun 15BioSmart Co.,Ltd. (KOSDAQ:038460) Might Not Be As Mispriced As It Looks After Plunging 26%The BioSmart Co.,Ltd. ( KOSDAQ:038460 ) share price has softened a substantial 26% over the previous 30 days, handing...Valuation Update With 7 Day Price Move • Jun 07Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₩4,530, the stock trades at a trailing P/E ratio of 5.3x. Average trailing P/E is 15x in the Tech industry in South Korea. Total loss to shareholders of 32% over the past three years.お知らせ • Jun 06An unknown buyer agreed to acquire a 13.33% stake in Tc Materials Co., Ltd. from BioSmart Co.,Ltd. (KOSDAQ:A038460) for KRW 10 billionAn unknown buyer agreed to acquire a 13.33% stake in Tc Materials Co., Ltd. from BioSmart Co.,Ltd. (KOSDAQ:A038460) for KRW 10 billion on June 4, 2024. The transaction is expected to close on June 5, 2024.Valuation Update With 7 Day Price Move • May 20Investor sentiment improves as stock rises 20%After last week's 20% share price gain to ₩6,560, the stock trades at a trailing P/E ratio of 8.1x. Average trailing P/E is 10x in the Tech industry in South Korea. Total returns to shareholders of 6.0% over the past three years.分析記事 • May 02Here's Why BioSmartLtd (KOSDAQ:038460) Has A Meaningful Debt BurdenLegendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Valuation Update With 7 Day Price Move • Apr 25Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₩4,505, the stock trades at a trailing P/E ratio of 5.2x. Average trailing P/E is 11x in the Tech industry in South Korea. Total loss to shareholders of 35% over the past three years.分析記事 • Apr 11Further Upside For BioSmart Co.,Ltd. (KOSDAQ:038460) Shares Could Introduce Price Risks After 52% BounceThe BioSmart Co.,Ltd. ( KOSDAQ:038460 ) share price has done very well over the last month, posting an excellent gain...New Risk • Apr 11New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.8x net interest cover). Earnings have declined by 17% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (9.9% average weekly change). Large one-off items impacting financial results. Shareholders have been diluted in the past year (7.0% increase in shares outstanding). Market cap is less than US$100m (₩109.1b market cap, or US$79.8m).Valuation Update With 7 Day Price Move • Apr 10Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₩4,090, the stock trades at a trailing P/E ratio of 4.7x. Average trailing P/E is 12x in the Tech industry in South Korea. Total loss to shareholders of 31% over the past three years.分析記事 • Mar 26Shareholders In BioSmartLtd (KOSDAQ:038460) Should Look Beyond Earnings For The Full StoryWe didn't see BioSmart Co.,Ltd.'s ( KOSDAQ:038460 ) stock surge when it reported robust earnings recently. We looked...Reported Earnings • Mar 23Full year 2023 earnings released: EPS: ₩915 (vs ₩38.00 in FY 2022)Full year 2023 results: EPS: ₩915 (up from ₩38.00 in FY 2022). Revenue: ₩456.2b (up 16% from FY 2022). Net income: ₩17.9b (up ₩17.2b from FY 2022). Profit margin: 3.9% (up from 0.2% in FY 2022). Over the last 3 years on average, earnings per share has increased by 124% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.Buy Or Sell Opportunity • Jan 19Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 12% to ₩3,370. The fair value is estimated to be ₩2,795, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 40% over the last 3 years. Earnings per share has grown by 87%.Valuation Update With 7 Day Price Move • Oct 25Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₩3,720, the stock trades at a trailing P/E ratio of 12.1x. Average trailing P/E is 12x in the Tech industry in South Korea. Total loss to shareholders of 65% over the past three years.New Risk • Oct 24New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.5x net interest cover). Earnings have declined by 31% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (9.2% average weekly change). Shareholders have been diluted in the past year (3.8% increase in shares outstanding). Market cap is less than US$100m (₩72.0b market cap, or US$53.6m).New Risk • Sep 01New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.8% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.5x net interest cover). Earnings have declined by 31% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (2.8% increase in shares outstanding). Market cap is less than US$100m (₩71.8b market cap, or US$54.2m).Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Valuation Update With 7 Day Price Move • Sep 28Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ₩3,070, the stock trades at a trailing P/E ratio of 54.3x. Average trailing P/E is 12x in the Tech industry in South Korea. Total loss to shareholders of 34% over the past three years.Valuation Update With 7 Day Price Move • Jul 12Investor sentiment improved over the past weekAfter last week's 15% share price gain to ₩4,515, the stock trades at a trailing P/E ratio of 29.8x. Average trailing P/E is 9x in the Tech industry in South Korea. Total loss to shareholders of 9.1% over the past three years.Valuation Update With 7 Day Price Move • Jun 15Investor sentiment deteriorated over the past weekAfter last week's 17% share price decline to ₩3,905, the stock trades at a trailing P/E ratio of 25.8x. Average trailing P/E is 10x in the Tech industry in South Korea. Total loss to shareholders of 14% over the past three years.Board Change • Apr 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.分析記事 • Mar 09Is BioSmartLtd (KOSDAQ:038460) Using Too Much Debt?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Is New 90 Day High Low • Mar 04New 90-day low: ₩6,140The company is down 19% from its price of ₩7,600 on 04 December 2020. The South Korean market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Tech industry, which is up 20% over the same period.分析記事 • Feb 16Returns On Capital At BioSmartLtd (KOSDAQ:038460) Paint An Interesting PictureThere are a few key trends to look for if we want to identify the next multi-bagger. One common approach is to try and...分析記事 • Jan 29Declining Stock and Decent Financials: Is The Market Wrong About BioSmart Co.,Ltd. (KOSDAQ:038460)?It is hard to get excited after looking at BioSmartLtd's (KOSDAQ:038460) recent performance, when its stock has...Is New 90 Day High Low • Jan 29New 90-day low: ₩6,230The company is down 37% from its price of ₩9,920 on 30 October 2020. The South Korean market is up 33% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Tech industry, which is up 48% over the same period.分析記事 • Jan 11BioSmartLtd (KOSDAQ:038460) Shareholders Have Enjoyed A 51% Share Price GainBioSmart Co.,Ltd. ( KOSDAQ:038460 ) shareholders might be concerned after seeing the share price drop 26% in the last...Is New 90 Day High Low • Jan 08New 90-day low: ₩7,280The company is down 28% from its price of ₩10,100 on 08 October 2020. The South Korean market is up 25% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Tech industry, which is up 39% over the same period.分析記事 • Dec 23BioSmart Co.,Ltd. (KOSDAQ:038460) Looks Interesting, And It's About To Pay A DividendBioSmart Co.,Ltd. ( KOSDAQ:038460 ) is about to trade ex-dividend in the next four days. Ex-dividend means that...Upcoming Dividend • Dec 22Upcoming Dividend of ₩63.00 Per ShareWill be paid on the 7th of April to those who are registered shareholders by the 29th of December. The trailing yield of 0.7% is below the top quartile of South Korean dividend payers (2.6%), and is lower than industry peers (1.9%).分析記事 • Dec 17Does BioSmart Co.,Ltd. (KOSDAQ:038460) Have A Place In Your Dividend Portfolio?Dividend paying stocks like BioSmart Co.,Ltd. ( KOSDAQ:038460 ) tend to be popular with investors, and for good reason...Valuation Update With 7 Day Price Move • Dec 16Investor sentiment improved over the past weekAfter last week's 29% share price gain to ₩9,670, the stock is trading at a trailing P/E ratio of 58.2x, up from the previous P/E ratio of 45x. This compares to an average P/E of 24x in the Tech industry in South Korea. Total returns to shareholders over the past three years are 110%.分析記事 • Nov 29These 4 Measures Indicate That BioSmartLtd (KOSDAQ:038460) Is Using Debt ExtensivelyWarren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...Is New 90 Day High Low • Nov 25New 90-day low: ₩8,150The company is down 36% from its price of ₩12,800 on 27 August 2020. The South Korean market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Tech industry, which is up 22% over the same period.Valuation Update With 7 Day Price Move • Nov 09Market bids up stock over the past weekAfter last week's 20% share price gain to ₩11,650, the stock is trading at a trailing P/E ratio of 11.6x, up from the previous P/E ratio of 9.6x. This compares to an average P/E of 16x in the Tech industry in South Korea. Total returns to shareholders over the past three years are 131%.Valuation Update With 7 Day Price Move • Oct 27Market bids up stock over the past weekAfter last week's 19% share price gain to ₩10,750, the stock is trading at a trailing P/E ratio of 10.7x, up from the previous P/E ratio of 8.9x. This compares to an average P/E of 20x in the Tech industry in South Korea. Total returns to shareholders over the past three years are 118%.収支内訳BioSmartLtd の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史KOSDAQ:A038460 収益、費用、利益 ( )KRW Millions日付収益収益G+A経費研究開発費31 Dec 25482,7769,00959,62669330 Sep 25475,0317,21557,64079430 Jun 25468,6061,72459,64173431 Mar 25477,902-2,20859,74976631 Dec 24484,31012759,07268030 Sep 24477,3377,12857,62195930 Jun 24472,3108,96058,92996631 Mar 24464,37719,48261,6501,12031 Dec 23456,16417,90764,1401,34130 Sep 23451,6934,46465,8881,46830 Jun 23430,6186,12165,3301,60731 Mar 23409,3442,03864,3971,32031 Dec 22391,82272162,7031,16830 Sep 22332,8562,35460,20938630 Jun 22287,7361,08458,96822531 Mar 22237,7882,90956,48532731 Dec 21189,1831,39256,41342730 Sep 21184,940-5,44058,50780430 Jun 21175,807-6,89158,0591,05131 Mar 21167,868-9,99057,8301,08831 Dec 20166,429-8,73755,5911,02930 Sep 20166,3953,24756,34593030 Jun 20167,21219,93054,69569031 Mar 20165,73220,84252,59556931 Dec 19158,96822,14749,54247730 Sep 19151,42618,04645,51741230 Jun 19143,9274,64641,38952431 Mar 19129,5296,74435,70953431 Dec 18117,7335,13531,41253430 Sep 18103,1088,64525,60456530 Jun 1892,4987,69121,07938431 Mar 1887,4895,58518,84825531 Dec 1780,4334,82616,99216830 Sep 1779,5132,59415,3759230 Jun 1774,7801,69714,2844931 Mar 1768,02749513,0937331 Dec 1662,99061911,9017930 Sep 1658,8151,61911,9769730 Jun 1655,9462,13412,12710231 Mar 1655,2041,61912,1079631 Dec 1554,1873,14811,6168830 Sep 1550,6362,17810,6917230 Jun 1546,4686509,64567質の高い収益: A038460は 高品質の収益 を持っています。利益率の向上: A038460の現在の純利益率 (1.9%)は、昨年(0.03%)よりも高くなっています。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: A038460過去 5 年間で収益を上げており、収益は年間48.3%増加しています。成長の加速: A038460の過去 1 年間の収益成長率 ( 6984.2% ) は、5 年間の平均 ( 年間48.3%を上回っています。収益対業界: A038460の過去 1 年間の収益成長率 ( 6984.2% ) はTech業界58%を上回りました。株主資本利益率高いROE: A038460の 自己資本利益率 ( 4.8% ) は 低い とみなされます。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YTech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/08 10:33終値2026/05/08 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋BioSmart Co.,Ltd. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Reported Earnings • Mar 22Full year 2024 earnings released: EPS: ₩6.00 (vs ₩915 in FY 2023)Full year 2024 results: EPS: ₩6.00 (down from ₩915 in FY 2023). Revenue: ₩484.3b (up 6.2% from FY 2023). Net income: ₩127.2m (down 99% from FY 2023). Profit margin: 0% (down from 3.9% in FY 2023). Over the last 3 years on average, earnings per share has increased by 49% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings.
分析記事 • Mar 26Shareholders In BioSmartLtd (KOSDAQ:038460) Should Look Beyond Earnings For The Full StoryWe didn't see BioSmart Co.,Ltd.'s ( KOSDAQ:038460 ) stock surge when it reported robust earnings recently. We looked...
Reported Earnings • Mar 23Full year 2023 earnings released: EPS: ₩915 (vs ₩38.00 in FY 2022)Full year 2023 results: EPS: ₩915 (up from ₩38.00 in FY 2022). Revenue: ₩456.2b (up 16% from FY 2022). Net income: ₩17.9b (up ₩17.2b from FY 2022). Profit margin: 3.9% (up from 0.2% in FY 2022). Over the last 3 years on average, earnings per share has increased by 124% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.
お知らせ • Mar 13BioSmart Co.,Ltd., Annual General Meeting, Mar 27, 2026BioSmart Co.,Ltd., Annual General Meeting, Mar 27, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 36-16, oncheon-daero 1122beon-gil, chungcheongnam-do, asan South Korea
Valuation Update With 7 Day Price Move • Mar 04Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₩4,360, the stock trades at a trailing P/E ratio of 15.3x. Average trailing P/E is 12x in the Tech industry in South Korea. Total returns to shareholders of 20% over the past three years.
分析記事 • Feb 02What BioSmart Co.,Ltd.'s (KOSDAQ:038460) 44% Share Price Gain Is Not Telling YouBioSmart Co.,Ltd. ( KOSDAQ:038460 ) shares have continued their recent momentum with a 44% gain in the last month...
New Risk • Feb 02New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 14% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (14% average weekly change). Minor Risk Market cap is less than US$100m (₩143.6b market cap, or US$99.1m).
Valuation Update With 7 Day Price Move • Feb 02Investor sentiment improves as stock rises 42%After last week's 42% share price gain to ₩5,680, the stock trades at a trailing P/E ratio of 19.9x. Average trailing P/E is 10x in the Tech industry in South Korea. Total returns to shareholders of 50% over the past three years.
分析記事 • Dec 15BioSmart Co.,Ltd.'s (KOSDAQ:038460) Shares Climb 44% But Its Business Is Yet to Catch UpBioSmart Co.,Ltd. ( KOSDAQ:038460 ) shares have had a really impressive month, gaining 44% after a shaky period...
New Risk • Dec 15New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (9.3% average weekly change). Market cap is less than US$100m (₩100.3b market cap, or US$68.5m).
Valuation Update With 7 Day Price Move • Dec 15Investor sentiment improves as stock rises 42%After last week's 42% share price gain to ₩3,970, the stock trades at a trailing P/E ratio of 13.9x. Average trailing P/E is 11x in the Tech industry in South Korea. Total returns to shareholders of 8.2% over the past three years.
New Risk • Aug 30New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended September 2013. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported September 2013 fiscal period end). Minor Risk Market cap is less than US$100m (₩74.9b market cap, or US$54.0m).
分析記事 • Apr 23The Market Lifts BioSmart Co.,Ltd. (KOSDAQ:038460) Shares 33% But It Can Do MoreBioSmart Co.,Ltd. ( KOSDAQ:038460 ) shareholders have had their patience rewarded with a 33% share price jump in the...
New Risk • Apr 23New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 0.8% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (10% average weekly change). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (0.03% net profit margin). Shareholders have been diluted in the past year (23% increase in shares outstanding). Market cap is less than US$100m (₩102.7b market cap, or US$72.2m).
分析記事 • Apr 09Is BioSmartLtd (KOSDAQ:038460) Using Too Much Debt?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Reported Earnings • Mar 22Full year 2024 earnings released: EPS: ₩6.00 (vs ₩915 in FY 2023)Full year 2024 results: EPS: ₩6.00 (down from ₩915 in FY 2023). Revenue: ₩484.3b (up 6.2% from FY 2023). Net income: ₩127.2m (down 99% from FY 2023). Profit margin: 0% (down from 3.9% in FY 2023). Over the last 3 years on average, earnings per share has increased by 49% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings.
お知らせ • Mar 12BioSmart Co.,Ltd., Annual General Meeting, Mar 26, 2025BioSmart Co.,Ltd., Annual General Meeting, Mar 26, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 36-16, oncheon-daero 1122beon-gil, chungcheongnam-do, asan South Korea
New Risk • Dec 08New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended September 2013. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported September 2013 fiscal period end). Minor Risks Shareholders have been diluted in the past year (25% increase in shares outstanding). Market cap is less than US$100m (₩74.2b market cap, or US$52.1m).
分析記事 • Nov 13BioSmart Co.,Ltd. (KOSDAQ:038460) May Have Run Too Fast Too Soon With Recent 25% Price PlummetThe BioSmart Co.,Ltd. ( KOSDAQ:038460 ) share price has fared very poorly over the last month, falling by a substantial...
分析記事 • Oct 14Here's Why We Think BioSmartLtd (KOSDAQ:038460) Is Well Worth WatchingFor beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
Valuation Update With 7 Day Price Move • Oct 14Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₩4,205, the stock trades at a trailing P/E ratio of 10.8x. Average trailing P/E is 9x in the Tech industry in South Korea. Total loss to shareholders of 21% over the past three years.
Valuation Update With 7 Day Price Move • Aug 26Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to ₩3,810, the stock trades at a trailing P/E ratio of 4.5x. Average trailing P/E is 9x in the Tech industry in South Korea. Total loss to shareholders of 42% over the past three years.
分析記事 • Aug 01BioSmartLtd (KOSDAQ:038460) Seems To Be Using A Lot Of DebtSome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
分析記事 • Jun 15BioSmart Co.,Ltd. (KOSDAQ:038460) Might Not Be As Mispriced As It Looks After Plunging 26%The BioSmart Co.,Ltd. ( KOSDAQ:038460 ) share price has softened a substantial 26% over the previous 30 days, handing...
Valuation Update With 7 Day Price Move • Jun 07Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₩4,530, the stock trades at a trailing P/E ratio of 5.3x. Average trailing P/E is 15x in the Tech industry in South Korea. Total loss to shareholders of 32% over the past three years.
お知らせ • Jun 06An unknown buyer agreed to acquire a 13.33% stake in Tc Materials Co., Ltd. from BioSmart Co.,Ltd. (KOSDAQ:A038460) for KRW 10 billionAn unknown buyer agreed to acquire a 13.33% stake in Tc Materials Co., Ltd. from BioSmart Co.,Ltd. (KOSDAQ:A038460) for KRW 10 billion on June 4, 2024. The transaction is expected to close on June 5, 2024.
Valuation Update With 7 Day Price Move • May 20Investor sentiment improves as stock rises 20%After last week's 20% share price gain to ₩6,560, the stock trades at a trailing P/E ratio of 8.1x. Average trailing P/E is 10x in the Tech industry in South Korea. Total returns to shareholders of 6.0% over the past three years.
分析記事 • May 02Here's Why BioSmartLtd (KOSDAQ:038460) Has A Meaningful Debt BurdenLegendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Valuation Update With 7 Day Price Move • Apr 25Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₩4,505, the stock trades at a trailing P/E ratio of 5.2x. Average trailing P/E is 11x in the Tech industry in South Korea. Total loss to shareholders of 35% over the past three years.
分析記事 • Apr 11Further Upside For BioSmart Co.,Ltd. (KOSDAQ:038460) Shares Could Introduce Price Risks After 52% BounceThe BioSmart Co.,Ltd. ( KOSDAQ:038460 ) share price has done very well over the last month, posting an excellent gain...
New Risk • Apr 11New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.8x net interest cover). Earnings have declined by 17% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (9.9% average weekly change). Large one-off items impacting financial results. Shareholders have been diluted in the past year (7.0% increase in shares outstanding). Market cap is less than US$100m (₩109.1b market cap, or US$79.8m).
Valuation Update With 7 Day Price Move • Apr 10Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₩4,090, the stock trades at a trailing P/E ratio of 4.7x. Average trailing P/E is 12x in the Tech industry in South Korea. Total loss to shareholders of 31% over the past three years.
分析記事 • Mar 26Shareholders In BioSmartLtd (KOSDAQ:038460) Should Look Beyond Earnings For The Full StoryWe didn't see BioSmart Co.,Ltd.'s ( KOSDAQ:038460 ) stock surge when it reported robust earnings recently. We looked...
Reported Earnings • Mar 23Full year 2023 earnings released: EPS: ₩915 (vs ₩38.00 in FY 2022)Full year 2023 results: EPS: ₩915 (up from ₩38.00 in FY 2022). Revenue: ₩456.2b (up 16% from FY 2022). Net income: ₩17.9b (up ₩17.2b from FY 2022). Profit margin: 3.9% (up from 0.2% in FY 2022). Over the last 3 years on average, earnings per share has increased by 124% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.
Buy Or Sell Opportunity • Jan 19Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 12% to ₩3,370. The fair value is estimated to be ₩2,795, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 40% over the last 3 years. Earnings per share has grown by 87%.
Valuation Update With 7 Day Price Move • Oct 25Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₩3,720, the stock trades at a trailing P/E ratio of 12.1x. Average trailing P/E is 12x in the Tech industry in South Korea. Total loss to shareholders of 65% over the past three years.
New Risk • Oct 24New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.5x net interest cover). Earnings have declined by 31% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (9.2% average weekly change). Shareholders have been diluted in the past year (3.8% increase in shares outstanding). Market cap is less than US$100m (₩72.0b market cap, or US$53.6m).
New Risk • Sep 01New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.8% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.5x net interest cover). Earnings have declined by 31% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (2.8% increase in shares outstanding). Market cap is less than US$100m (₩71.8b market cap, or US$54.2m).
Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Valuation Update With 7 Day Price Move • Sep 28Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ₩3,070, the stock trades at a trailing P/E ratio of 54.3x. Average trailing P/E is 12x in the Tech industry in South Korea. Total loss to shareholders of 34% over the past three years.
Valuation Update With 7 Day Price Move • Jul 12Investor sentiment improved over the past weekAfter last week's 15% share price gain to ₩4,515, the stock trades at a trailing P/E ratio of 29.8x. Average trailing P/E is 9x in the Tech industry in South Korea. Total loss to shareholders of 9.1% over the past three years.
Valuation Update With 7 Day Price Move • Jun 15Investor sentiment deteriorated over the past weekAfter last week's 17% share price decline to ₩3,905, the stock trades at a trailing P/E ratio of 25.8x. Average trailing P/E is 10x in the Tech industry in South Korea. Total loss to shareholders of 14% over the past three years.
Board Change • Apr 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
分析記事 • Mar 09Is BioSmartLtd (KOSDAQ:038460) Using Too Much Debt?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Is New 90 Day High Low • Mar 04New 90-day low: ₩6,140The company is down 19% from its price of ₩7,600 on 04 December 2020. The South Korean market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Tech industry, which is up 20% over the same period.
分析記事 • Feb 16Returns On Capital At BioSmartLtd (KOSDAQ:038460) Paint An Interesting PictureThere are a few key trends to look for if we want to identify the next multi-bagger. One common approach is to try and...
分析記事 • Jan 29Declining Stock and Decent Financials: Is The Market Wrong About BioSmart Co.,Ltd. (KOSDAQ:038460)?It is hard to get excited after looking at BioSmartLtd's (KOSDAQ:038460) recent performance, when its stock has...
Is New 90 Day High Low • Jan 29New 90-day low: ₩6,230The company is down 37% from its price of ₩9,920 on 30 October 2020. The South Korean market is up 33% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Tech industry, which is up 48% over the same period.
分析記事 • Jan 11BioSmartLtd (KOSDAQ:038460) Shareholders Have Enjoyed A 51% Share Price GainBioSmart Co.,Ltd. ( KOSDAQ:038460 ) shareholders might be concerned after seeing the share price drop 26% in the last...
Is New 90 Day High Low • Jan 08New 90-day low: ₩7,280The company is down 28% from its price of ₩10,100 on 08 October 2020. The South Korean market is up 25% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Tech industry, which is up 39% over the same period.
分析記事 • Dec 23BioSmart Co.,Ltd. (KOSDAQ:038460) Looks Interesting, And It's About To Pay A DividendBioSmart Co.,Ltd. ( KOSDAQ:038460 ) is about to trade ex-dividend in the next four days. Ex-dividend means that...
Upcoming Dividend • Dec 22Upcoming Dividend of ₩63.00 Per ShareWill be paid on the 7th of April to those who are registered shareholders by the 29th of December. The trailing yield of 0.7% is below the top quartile of South Korean dividend payers (2.6%), and is lower than industry peers (1.9%).
分析記事 • Dec 17Does BioSmart Co.,Ltd. (KOSDAQ:038460) Have A Place In Your Dividend Portfolio?Dividend paying stocks like BioSmart Co.,Ltd. ( KOSDAQ:038460 ) tend to be popular with investors, and for good reason...
Valuation Update With 7 Day Price Move • Dec 16Investor sentiment improved over the past weekAfter last week's 29% share price gain to ₩9,670, the stock is trading at a trailing P/E ratio of 58.2x, up from the previous P/E ratio of 45x. This compares to an average P/E of 24x in the Tech industry in South Korea. Total returns to shareholders over the past three years are 110%.
分析記事 • Nov 29These 4 Measures Indicate That BioSmartLtd (KOSDAQ:038460) Is Using Debt ExtensivelyWarren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...
Is New 90 Day High Low • Nov 25New 90-day low: ₩8,150The company is down 36% from its price of ₩12,800 on 27 August 2020. The South Korean market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Tech industry, which is up 22% over the same period.
Valuation Update With 7 Day Price Move • Nov 09Market bids up stock over the past weekAfter last week's 20% share price gain to ₩11,650, the stock is trading at a trailing P/E ratio of 11.6x, up from the previous P/E ratio of 9.6x. This compares to an average P/E of 16x in the Tech industry in South Korea. Total returns to shareholders over the past three years are 131%.
Valuation Update With 7 Day Price Move • Oct 27Market bids up stock over the past weekAfter last week's 19% share price gain to ₩10,750, the stock is trading at a trailing P/E ratio of 10.7x, up from the previous P/E ratio of 8.9x. This compares to an average P/E of 20x in the Tech industry in South Korea. Total returns to shareholders over the past three years are 118%.